Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hypertrophy/obezite
Bağlantı panoya kaydedilir
Sayfa 1 itibaren 32 Sonuçlar
Use of droloxifene for the treatment of protastic disease, endometriosis and obesity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
This invention relates to remedies for prostate diseases, endometriosis and obesity comprising, as active ingredient, droloxifene having the chemical structure represented by the following formula, ##STR1## or a pharmaceutically acceptable salt thereof.
BACKGROUND OF THE
Bacteroides CECT 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
CROSS-REFERENCE TO RELATED APPLICATIONS
This U.S. patent application is a national stage application under 35 U.S.C. .sctn.371 of international application PCT/ES2013/070309, filed May 16, 2013, and claims the benefit of priority under 35 U.S.C. .sctn.119 of Spanish Patent Application No. 201230796,
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Regulation of metabolism by miR-378
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: MIRG.sub.--022.sub.--01WO_SeqList_ST25.txt, date recorded:
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto.
BACKGROUND OF THE INVENTION
The estrogen hormone has a broad spectrum of effects on tissues in
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto.
BACKGROUND OF THE INVENTION
The estrogen hormone has a broad spectrum of effects on tissues in
Method for regulating size of vascularized normal tissue
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention is directed generally to the field of treatment of obesity and other disorders characterized by proliferation of normal vascularized tissues, by the administration of effective amount of angiogenesis inhibitors.
BACKGROUND OF THE INVENTION
The prevalence
N-benzylindole modulators of PPARG
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes, such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
N-biphenylmethylindole modulators of PPARG
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
Compounds and methods for modulation of estrogen receptors
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods
Cardioprotective phosphonates and malonates
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
This invention relates to pyridoxine phosphonate analogues, to pyridoxine malonate analogues, to their preparation, to pharmaceutical compositions thereof, and to treatments for cardiovascular and related diseases, for example, hypertrophy, hypertension, congestive heart
Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı
- 55 dilde çalışır
- Bilim destekli bitkisel kürler
- Görüntüye göre bitki tanıma
- Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
- Aramanızla ilgili bilimsel yayınları okuyun
- Şifalı bitkileri etkilerine göre arayın
- İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın
Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır
